HUE063026T2 - Eljárások és készítmények LDHA expressziójának gátlására - Google Patents
Eljárások és készítmények LDHA expressziójának gátlásáraInfo
- Publication number
- HUE063026T2 HUE063026T2 HUE18867097A HUE18867097A HUE063026T2 HU E063026 T2 HUE063026 T2 HU E063026T2 HU E18867097 A HUE18867097 A HU E18867097A HU E18867097 A HUE18867097 A HU E18867097A HU E063026 T2 HUE063026 T2 HU E063026T2
- Authority
- HU
- Hungary
- Prior art keywords
- ldha
- compositions
- methods
- inhibiting expression
- inhibiting
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 101150041530 ldha gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572403P | 2017-10-13 | 2017-10-13 | |
| US201762572398P | 2017-10-13 | 2017-10-13 | |
| US201862726950P | 2018-09-04 | 2018-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE063026T2 true HUE063026T2 (hu) | 2023-12-28 |
Family
ID=66101691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18867097A HUE063026T2 (hu) | 2017-10-13 | 2018-10-12 | Eljárások és készítmények LDHA expressziójának gátlására |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11286488B2 (hu) |
| EP (2) | EP4265261A3 (hu) |
| JP (2) | JP7308213B2 (hu) |
| KR (2) | KR102609396B1 (hu) |
| CN (3) | CN111448319B (hu) |
| AU (1) | AU2018346971A1 (hu) |
| CA (1) | CA3078933A1 (hu) |
| ES (1) | ES2955045T3 (hu) |
| HR (1) | HRP20231063T1 (hu) |
| HU (1) | HUE063026T2 (hu) |
| IL (1) | IL273875A (hu) |
| MX (1) | MX2020003836A (hu) |
| PL (1) | PL3679141T3 (hu) |
| RS (1) | RS64483B1 (hu) |
| WO (1) | WO2019075419A1 (hu) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057932A1 (en) | 2014-10-10 | 2016-04-14 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| EP3334499A4 (en) | 2015-08-14 | 2019-04-17 | University of Massachusetts | BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES |
| HUE063026T2 (hu) | 2017-10-13 | 2023-12-28 | Novo Nordisk Healthcare Ag | Eljárások és készítmények LDHA expressziójának gátlására |
| EP3684377B1 (en) * | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| KR20200109311A (ko) | 2018-01-16 | 2020-09-22 | 다이서나 파마수이티컬, 인크. | Aldh2 발현을 억제하기 위한 조성물 및 방법 |
| MX2022001710A (es) | 2019-08-09 | 2022-05-10 | Univ Massachusetts | Oligonucleótidos modificados químicamente dirigidos a los snp. |
| JP2022545118A (ja) * | 2019-08-23 | 2022-10-25 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| IL291841A (en) * | 2019-10-02 | 2022-06-01 | Dicerna Pharmaceuticals Inc | Chemical modifications of tiny interfering rna with minimal fluoride content |
| EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| WO2021234543A1 (en) * | 2020-05-18 | 2021-11-25 | Chinook Therapeutics Canada, Inc. | Substituted pyrazolyl compounds and methods of use thereof |
| MX2023005627A (es) * | 2020-11-13 | 2023-05-24 | Dicerna Pharmaceuticals Inc | Modificaciones quimicas para inhibir la expresion de aldh2. |
| CN117836304A (zh) | 2021-03-19 | 2024-04-05 | 巴克姆股份公司 | 改进的寡核苷酸合成 |
| WO2022214692A1 (en) | 2021-04-09 | 2022-10-13 | Bachem Holding Ag | Pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates |
| AU2022261359A1 (en) * | 2021-04-19 | 2023-10-12 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| US11649260B2 (en) | 2021-06-18 | 2023-05-16 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine nucleosides |
| TW202333748A (zh) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物 |
| US20230107967A1 (en) * | 2021-08-25 | 2023-04-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting alpha-1 antitrypsin expression |
| US11692001B2 (en) | 2021-08-30 | 2023-07-04 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| AR127260A1 (es) * | 2021-10-05 | 2024-01-03 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para inhibir el receptor de melanocortina 2 y la expresión del citocromo p450 11b |
| WO2023114746A1 (en) | 2021-12-15 | 2023-06-22 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| WO2024061842A1 (en) | 2022-09-19 | 2024-03-28 | Bachem Holding Ag | Improved oligonucleotide synthesis |
| WO2024061157A1 (en) * | 2022-09-19 | 2024-03-28 | Kylonova (Xiamen) Biopharma Co., Ltd. | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications |
| WO2024083746A1 (en) | 2022-10-17 | 2024-04-25 | Bachem Holding Ag | Method and composition for oligonucleotide synthesis |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10920226B2 (en) | 2002-11-14 | 2021-02-16 | Thermo Fisher Scientific Inc. | siRNA targeting LDHA |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20050014692A1 (en) | 2003-01-21 | 2005-01-20 | Newgard Christopher B. | Lactate dehydrogenase as a novel target and reagent for diabetes therapy |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| CA2559955C (en) | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| KR20070085113A (ko) | 2004-05-11 | 2007-08-27 | 가부시키가이샤 알파젠 | Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법 |
| CN102037123A (zh) * | 2008-04-04 | 2011-04-27 | 卡兰多制药股份有限公司 | Epas1抑制剂的组合物和用途 |
| WO2010002465A2 (en) | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| US20110288147A1 (en) | 2008-09-22 | 2011-11-24 | Bob Dale Brown | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop |
| AU2009293636A1 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsRNA possessing modifications |
| US20100173973A1 (en) | 2008-12-18 | 2010-07-08 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| CN108524505A (zh) | 2009-03-13 | 2018-09-14 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| EP2539451B1 (en) | 2010-02-24 | 2016-01-06 | Arrowhead Research Corporation | Compositions for targeted delivery of sirna |
| PL2576580T3 (pl) | 2010-05-28 | 2017-03-31 | F.Hoffmann-La Roche Ag | Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej |
| WO2012156513A1 (en) | 2011-05-18 | 2012-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for determining whether a subject is at risk of having or developing a chronic kidney disease |
| JP2015502931A (ja) | 2011-11-18 | 2015-01-29 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 修飾ＲＮＡｉ剤 |
| TWI595885B (zh) | 2012-05-02 | 2017-08-21 | 喜納製藥公司 | 包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法 |
| WO2016057932A1 (en) | 2014-10-10 | 2016-04-14 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| CN109517878A (zh) | 2014-12-18 | 2019-03-26 | 加利福尼亚大学董事会 | 使用纳米管的核酸聚合酶构象变化的检测 |
| AR104754A1 (es) * | 2015-05-29 | 2017-08-09 | Arrowhead Pharmaceuticals Inc | Agentes de unión de tetrapéptido escindibles biológicamente |
| HUE063026T2 (hu) | 2017-10-13 | 2023-12-28 | Novo Nordisk Healthcare Ag | Eljárások és készítmények LDHA expressziójának gátlására |
-
2018
- 2018-10-12 HU HUE18867097A patent/HUE063026T2/hu unknown
- 2018-10-12 EP EP23172235.6A patent/EP4265261A3/en active Pending
- 2018-10-12 CN CN201880080394.2A patent/CN111448319B/zh active Active
- 2018-10-12 KR KR1020207013207A patent/KR102609396B1/ko active IP Right Grant
- 2018-10-12 PL PL18867097.0T patent/PL3679141T3/pl unknown
- 2018-10-12 CN CN202410538408.8A patent/CN118440940A/zh active Pending
- 2018-10-12 MX MX2020003836A patent/MX2020003836A/es unknown
- 2018-10-12 CN CN202410538409.2A patent/CN118530989A/zh active Pending
- 2018-10-12 WO PCT/US2018/055735 patent/WO2019075419A1/en active Application Filing
- 2018-10-12 HR HRP20231063TT patent/HRP20231063T1/hr unknown
- 2018-10-12 US US16/755,342 patent/US11286488B2/en active Active
- 2018-10-12 CA CA3078933A patent/CA3078933A1/en active Pending
- 2018-10-12 KR KR1020237041035A patent/KR20230169413A/ko active Search and Examination
- 2018-10-12 RS RS20230689A patent/RS64483B1/sr unknown
- 2018-10-12 AU AU2018346971A patent/AU2018346971A1/en active Pending
- 2018-10-12 EP EP18867097.0A patent/EP3679141B1/en active Active
- 2018-10-12 JP JP2020542046A patent/JP7308213B2/ja active Active
- 2018-10-12 ES ES18867097T patent/ES2955045T3/es active Active
-
2020
- 2020-04-07 IL IL273875A patent/IL273875A/en unknown
- 2020-09-16 US US17/022,696 patent/US11661604B2/en active Active
-
2022
- 2022-11-29 US US18/071,424 patent/US20240182901A1/en active Pending
-
2023
- 2023-07-03 JP JP2023109290A patent/JP2023139014A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019075419A1 (en) | 2019-04-18 |
| KR102609396B1 (ko) | 2023-12-01 |
| US20210062199A1 (en) | 2021-03-04 |
| EP4265261A3 (en) | 2024-01-24 |
| PL3679141T3 (pl) | 2023-10-02 |
| KR20230169413A (ko) | 2023-12-15 |
| EP3679141B1 (en) | 2023-06-07 |
| EP3679141A1 (en) | 2020-07-15 |
| MX2020003836A (es) | 2020-11-06 |
| CN111448319B (zh) | 2024-05-17 |
| IL273875A (en) | 2020-05-31 |
| CA3078933A1 (en) | 2019-04-18 |
| CN118530989A (zh) | 2024-08-23 |
| CN111448319A (zh) | 2020-07-24 |
| US20200283775A1 (en) | 2020-09-10 |
| KR20200078530A (ko) | 2020-07-01 |
| US20240182901A1 (en) | 2024-06-06 |
| EP3679141A4 (en) | 2021-06-16 |
| EP3679141C0 (en) | 2023-06-07 |
| JP2023139014A (ja) | 2023-10-03 |
| JP2020536587A (ja) | 2020-12-17 |
| EP4265261A2 (en) | 2023-10-25 |
| CN118440940A (zh) | 2024-08-06 |
| US11661604B2 (en) | 2023-05-30 |
| AU2018346971A1 (en) | 2020-04-23 |
| HRP20231063T1 (hr) | 2023-12-22 |
| ES2955045T3 (es) | 2023-11-28 |
| US11286488B2 (en) | 2022-03-29 |
| JP7308213B2 (ja) | 2023-07-13 |
| RS64483B1 (sr) | 2023-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273875A (en) | Methods and compounds for inhibiting expression of LDHA | |
| IL290566A (en) | Preparations and methods for preventing lipoprotein A gene expression | |
| HUS2200011I1 (hu) | Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására | |
| IL268788A (en) | Preparations and methods for increased gene expression | |
| IL254518A0 (en) | Preparations and methods for suppressing the expression of the factor xii gene | |
| HK1251610A1 (zh) | 用於抑制因子d的組合物和方法 | |
| HK1232163A1 (zh) | 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 | |
| HK1252852A1 (zh) | 阻止HIF2α基因表達的組合物及方法 | |
| EP3349743A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING DCN1-UBC12 INTERACTION | |
| IL271680A (en) | Compositions and methods for inhibiting expression of HMGB1 | |
| EP3105327A4 (en) | Compositions and methods of using microrna inhibitors | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| HK1252057A1 (zh) | 新穎的使用方法和組合物 | |
| EP3687628A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING ACSS2 | |
| HK1250145A1 (zh) | 治療多發性骨髓瘤的組合物和方法 | |
| HUE044559T2 (hu) | Lerakódást gátló készítmények és alkalmazási eljárásaik | |
| EP3237619B8 (en) | Compositions and methods for inhibiting expression of adamts-5 and adam17 | |
| EP3313399A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING RIT1 | |
| EP3681873A4 (en) | N-SMASE2 INHIBITION COMPOSITIONS AND METHODS | |
| SG11201704282UA (en) | Compositions and methods for the treatment of multiple sclerosis |